Immune Globulin Subcutaenous (Human), 20%

NCT01412385 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Immunodeficiency Diseases (PID)

Interventions

BIOLOGICAL: Immune Globulin Subcutaneous (Human), 20%
BIOLOGICAL: Immune Globulin Intravenous (Human), 10%
BIOLOGICAL: Human Normal Immunoglobulin (Subcutaneous - Intramuscular Immunoglobulin)

Sponsor

Baxalta now part of Shire